Most existing therapeutic agents for osteoporosis are anti-resorptive agents, such as bisphosphonates and anti-RANKL (receptor activator of nuclear factor κB ligand) antibody, inhibitors of osteoclast (OC) differentiation and bone resorption. Here, TNFSF11 is linked to osteoporosis.